Comparing Alirocumab vs Evolocumab
| Alirocumab | Evolocumab |
|
|---|
| Alirocumab | Evolocumab |
|
|---|---|---|
|
Prescription only
Prescribed for High Cholesterol - Familial Homozygous, Cardiovascular Risk Reduction, High Cholesterol, High Cholesterol - Familial Heterozygous. Alirocumab may also be used for purposes not listed... View more |
Prescription only
Prescribed for High Cholesterol - Familial Heterozygous, Cardiovascular Risk Reduction, High Cholesterol - Familial Homozygous, High Cholesterol. Evolocumab may also be used for purposes not listed... View more |
Related suggestions High Cholesterol
Cardiovascular Risk Reduction
High Cholesterol, Familial Heterozygous
High Cholesterol, Familial Homozygous
|
| More about Alirocumab | More about Evolocumab | |
| Ratings & Reviews | ||
|
Alirocumab has an average rating of 6.2 out of 10 from a total of 313 ratings on Drugs.com. 48% of reviewers reported a positive effect, while 31% reported a negative effect. |
Evolocumab has an average rating of 5.3 out of 10 from a total of 703 ratings on Drugs.com. 39% of reviewers reported a positive effect, while 45% reported a negative effect. |
|
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||
View all Alirocumab side effects |
View all Evolocumab side effects |
|
| Drug Class | ||
| Generic Availability | ||
|
N/A |
N/A |
|
| Pricing and Coupons * Prices are without insurance | ||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
|
| Dosage Forms | ||
|
N/A |
N/A |
|
| Brand Names | ||
| Praluent | Repatha | |
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||
|
480 hours |
408 hours |
|
| CSA Schedule 1 View glossary of CSA terms | ||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
|
| Pregnancy Category | ||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
|
| Drug Interactions | ||
|
A total of 2 drugs are known to interact with Alirocumab:
|
A total of 2 drugs are known to interact with Evolocumab:
|
|
| Alcohol/Food/Lifestyle Interactions | ||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
| Disease Interactions | ||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
| First Approval Date | ||
|
July 24, 2015 |
N/A |
|
| WADA Class View classifications | ||
|
N/A |
N/A |
|
| More Information | ||
| Patient Resources | ||
| Professional Resources | ||
| Related Treatment Guide | ||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.